RGENRepligen Corporation

$173.84+42% 1Y

$173.84

$102.8752 weeks$194.62

Is the price fair?

Watch

A demanding price: priced for +23% a year vs +3% a year delivered, at the top of its own P/E range, and rich vs its sector.

3 to watch

What the price assumes~+23% a year

Priced for ~23% a year FCF growth. The price demands more than its three-year revenue growth of 3% a year, priced for acceleration.

Vs its own P/E rangedearest in 33 quartersderived

Expensive vs its own history: P/E 238.1 vs a 111.5 median over 33 quarters (+114% vs median).

Vs sector (EV/EBIT)122.8×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 1% of the market

FCF yieldbottom 9% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What RGEN's price assumes

Repligen Corporation trades at 238× earnings against 39.6× for the median Medical Instruments & Supplies name, more expensive than its own group.

238

Trailing P/E · Medical Instruments & Supplies median 39.6 · 6.01× the median: the market pays up for this one

Price / sales: 10.4
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 1.4%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
Growth the price implies: +23%
Growth the price implies · The price pays for +23% free cash flow growth a year for a decade; the business has delivered +3.9% a year over the last three.